All In Biotech

Drug Trial Radar · NCT04046224

Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)

A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects With Fabry Disease (STAAR)

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

36

Actual

Start

Jul 23, 2019

Primary completion

Apr 10, 2025

Study completion Apr 10, 2025

Sponsor

Lead sponsor
Sangamo TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 6, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is the first in human treatment with ST-920, an adeno-associated virus (AAV2/6) vector encoding the complementary deoxyribonucleic acid (cDNA) for human a-Gal A. The purpose of this study is to evaluate the safety and tolerability of ascending doses of ST-920. ST-920 aims to provide stable, long-term production of α-Gal A at therapeutic levels in subjects with Fabry disease. The constant production of α-Gal A in humans should, importantly, enable reduction and potentially clearance of Fabry disease substrates Gb3 and lyso-Gb3. On Day 1, patients will be infused intravenously with a single dose of ST-920 and followed for a period of 52 weeks.

Conditions

  • Fabry Disease

Interventions

  • ST-920Biological

    Single dose of investigational product ST-920

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-emergent Adverse Events (TEAEs) - AllTime frame: Up to 12 months after the ST-920 infusion
  2. Incidence of Treatment-emergent Adverse Events (TEAEs) - Related to ST-920Time frame: Up to 12 months post ST-920 infusion
  3. Incidence of Treatment-emergent Adverse Events (TEAEs) - SeriousTime frame: Up to 12 month post ST-920 infusion
  4. Incidence of Treatment-emergent Adverse Events (TEAEs) - Any TEAEs Leading to Study Discontinuation or WithdrawalTime frame: Up to 12 month post ST-920 infusion

Locations

18 sites in 7 countries. Site status is shown where the registry gives one.

  • University of California, Irvine

    Irvine, California

  • University of South Florida

    Tampa, Florida

  • Emory University School of Medicine

    Atlanta, Georgia

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • University of Iowa Hospital and Clinics

    Iowa City, Iowa

  • University of Minnesota Medical Center

    Minneapolis, Minnesota

  • Mt. Sinai School of Medicine

    New York, New York

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)

    Fairfax, Virginia

  • The Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • M.A.G.I.C. Clinic Ltd.

    Calgary, Alberta, Canada

  • University Medical Center Hamburg-Eppendorf

    Hamburg, Germany

  • University Hospital of Würzburg

    Würzburg, Germany

  • Azienda Ospedaliero-Universitaria Careggi

    Florence, Tuscany, Italy

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Queen Elizabeth Hospital

    Birmingham, United Kingdom

  • Addenbrooke's Hospital

    Cambridge, United Kingdom

  • Royal Free Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.